Raising the standard for compounded peptides: research with the printer in Tennessee
As peptides open up to 503A compounding, one question matters most: are compounded peptides safe, and do they work? Benjamin Myatt of DCA Pharmacy in Franklin, Tennessee, believes compounders have a responsibility to answer it, and he’s using the CurifyLabs printer to do that.
His pharmacy already relies on the printer for its workflow and for the trust it gives them in what they produce. Now they’re running a clinical study of BPC-157 made on the printer. The study has two goals. The first is bioavailability: confirming that the dosage form reaches adequate blood levels. The second is effectiveness, with tendon repair and injury recovery as the primary outcome.
The key, he says, is repeatability. You can only study something properly if you can make it the same way every time, and a printer “removes all doubt.” Once a dosage form is shown to work, he hopes pharmacies anywhere in the US can compound it the same way, in a form that’s comfortable and accessible for patients.
He also credits the CurifyLabs team for support at every step, from formulation design to connecting the pharmacy with testing partners.
Watch the full conversation below.
.png)
